Enel Health®Atlas
Sign in
Enel Health®Atlas
Browse libraries

Not medical advice. The Atlas is not a substitute for a clinician who can examine you.

The 'Low T' Marketing Era & the 2015 FDA Reckoning

How Testosterone Became a Mass-Market Product, and the Regulatory Backlash

Evidence grade 3 of 5, Mixed. Read how the Atlas grades evidence.

The written rationale for this grade is still being prepared.

FDA
Testosterone products approved for hypogonadism; 2015 FDA label changes

Reference only. Not medical advice.

What can go wrong

The 2015 FDA action warned of possible increased cardiovascular risk and limited approved use to diagnosed hypogonadism. Testosterone therapy can also suppress fertility and requires monitoring. Inappropriate use driven by marketing carries risk without established benefit.

This is something to take to a clinician. The Atlas can tell you what is known about the 'low t' marketing era & the 2015 fda reckoning in general. It cannot tell you what is happening in your body, and the difference matters most for exactly the symptoms that bring people to this page.

From the late 2000s into the early 2010s, manufacturers including Abbott/AbbVie (AndroGel) and Eli Lilly heavily promoted 'Low T,' framing the normal symptoms of aging as a treatable testosterone-deficiency syndrome and driving a surge in prescriptions. After two 2013-2014 studies linked testosterone therapy to cardiovascular events, the FDA convened an advisory committee in September 2014 and, in March 2015, revised testosterone labeling to warn of possible cardiovascular risk and to restrict approved use to men with diagnosed hypogonadism, not aging alone.

A marketing campaign turned aging into a diagnosis, until the FDA pushed back.

What people take it for

These are the reasons people give for taking it. They are not effects it has been shown to have.

  • Testosterone replacement for clinically diagnosed hypogonadism (the legitimate indication)
  • Marketed broadly for age-related symptoms (the contested 'Low T' framing)

How it is supposed to work

Testosterone replacement restores serum testosterone in men with genuine hypogonadism. The 'Low T' controversy concerned not the mechanism but the population: marketing extended use to aging men without a hypogonadism diagnosis, where benefit-risk is far less clear.

Safety in detail

Testosterone therapy involves significant physiological effects and requires evaluation and monitoring by a qualified physician. It is approved for diagnosed hypogonadism, not for symptoms of normal aging, and self-administration carries documented health risks.

What it does to fertility

Exogenous testosterone suppresses the hypothalamic-pituitary-gonadal axis and can impair sperm production and fertility, a risk frequently underemphasized in 'Low T' marketing aimed at men of reproductive age.

What has to be monitored

The bloodwork this needs, and the reason it belongs with a clinician rather than a website.

  • Serum testosterone
  • Hematocrit / hemoglobin
  • PSA
  • Cardiovascular risk assessment
  • Symptom and hypogonadism-diagnosis confirmation

What people get wrong

  • Often saidLow testosterone from aging is a disease that needs treatment

    ActuallyThe FDA explicitly limited approved testosterone use to diagnosed hypogonadism, not age-related decline. Treating aging alone with testosterone is not an approved indication.

  • Often saidThe 'Low T' marketing reflected established medical consensus

    ActuallyIt largely preceded the evidence; the marketing surge drove prescribing, and the FDA later pushed back on both the safety claims and the broad indication.

Who profits, and who pushes back

Nobody is named here yet, because we have not done that work on this entry. Read that as unfinished. Somebody almost certainly sells this, and somebody almost certainly disputes it. Assume both until we have checked.

How we got here

For most of its clinical history, testosterone therapy was a niche treatment for men with diagnosed hypogonadism. That changed in the late 2000s. Drugmakers, most prominently AbbVie with its topical gel AndroGel, along with Eli Lilly and others, launched aggressive direct-to-consumer and physician marketing built around the brandable phrase 'Low T.' The campaigns recast common, often nonspecific symptoms of aging, fatigue, reduced libido, low mood, weight gain, as signs of a treatable testosterone deficiency, encouraging men to 'ask your doctor' and get tested. U.S. testosterone prescriptions climbed dramatically, with a substantial share going to men who lacked a clear hypogonadism diagnosis. The reckoning came when two studies in 2013 and 2014 reported associations between testosterone therapy and increased cardiovascular events such as heart attack and stroke. The FDA began a safety review in early 2014 and held a widely publicized advisory committee meeting in September 2014. In March 2015 the agency revised the labeling of all approved testosterone products: it added a warning about possible increased cardiovascular risk and, crucially, stated that testosterone was approved only for men with low levels due to specific medical conditions (primary or secondary hypogonadism), not for low testosterone simply due to aging. The episode is a defining case study in how disease-awareness marketing can outrun the evidence base, and how regulators can recalibrate. The science continued to evolve: the large TRAVERSE cardiovascular outcomes trial later provided reassurance on cardiovascular safety in appropriately selected hypogonadal men, prompting further label updates, but the central lesson of the 'Low T' era, that aging itself is not an approved indication, endures.

  1. Late 2000s'Low T' direct-to-consumer marketing campaigns launch
  2. 2008-2013U.S. testosterone prescriptions surge, many without clear hypogonadism diagnosis
  3. 2013-2014Two studies link testosterone therapy to cardiovascular events
  4. January 2014FDA begins safety review of testosterone products
  5. September 2014FDA advisory committee meeting on testosterone safety
  6. March 2015FDA revises labels: cardiovascular warning; use restricted to diagnosed hypogonadism
  7. 2023TRAVERSE trial provides cardiovascular-safety data in selected hypogonadal men

At a glance

Marketing era peak
Roughly 2008-2013
Flagship product
AndroGel (AbbVie)
Trigger studies
2013-2014 cardiovascular-risk reports
FDA advisory committee
September 2014
FDA label change
March 2015
Restriction
Approved use limited to diagnosed hypogonadism, not aging

What this entry does not yet cover

What follows is unfinished work on our side, not a finding about The 'Low T' Marketing Era & the 2015 FDA Reckoning. A short entry is not a safe entry.

  • Cost and market. We have not documented what it sells for or who sells it.
  • Supply chain. We have not mapped where it is made.
  • Who uses it. We have not documented the user groups.
  • What could change. No forward-looking summary yet.
  • How it compares. We have not set it against the alternatives.
  • Children and teenagers. We have not checked what is known about younger people.
  • Where we land. We have not taken a position on this yet.

Sources

The studies below are named and described, but not linked. You cannot open them from here and check our reading against them, which means this page is our summary of the literature rather than a document you can verify. Weigh it accordingly until the links exist.

The studies that matter

  • FDA testosterone label revision2015

    Added cardiovascular warning and restricted approved use to diagnosed hypogonadism

  • TRAVERSE cardiovascular outcomes trial2023

    Provided cardiovascular-safety data in selected hypogonadal men, informing later label updates